TY - JOUR
T1 - Importance of lymph node immune responses in MSI-H/dMMR colorectal cancer
AU - Inamori, Koji
AU - Togashi, Yosuke
AU - Fukuoka, Shota
AU - Akagi, Kiwamu
AU - Ogasawara, Kouetsu
AU - Irie, Takuma
AU - Motooka, Daisuke
AU - Kobayashi, Yoichi
AU - Sugiyama, Daisuke
AU - Kojima, Motohiro
AU - Shiiya, Norihiko
AU - Nakamura, Shota
AU - Maruyama, Shoichi
AU - Suzuki, Yutaka
AU - Ito, Masaaki
AU - Nishikawa, Hiroyoshi
N1 - Funding Information:
We thank Y. Tada, T. Takaku, M. Nakai, K. Onagawa, M. Takemura, C. Haijima, M. Hoshino, K. Yoshida, Y. Osada, Y. Suto, and M. Ozawa for their technical assistance. This study was supported by Grants-in-Aid for Scientific Research (S grant no. 17H06162 [HN], B grant no. 20H03694 [YT], Young Scientists no. 17J09900 [YT], Challenging Exploratory Research no. 19K22574 [YT], and JSPS Research fellow no. 17K18388 [YT]) from the Ministry of Education, Culture, Sports, Science and Technology of Japan; by Japan Agency for Medical Research and Development (AMED -CREST [JP18gm1010005 (SN, MI, and HN)]), the Project for Cancer Research and Therapeutic Evolution (P-CREATE, no. 16cm0106301h0002 [HN] and no. 18cm0106340h0001 [YT]), Practical Research for Innovative Cancer Control (19ck0106521h0001 [YT]), and the Development of Technology for Patient Stratification Biomarker Discovery grant (no. 19ae0101074s0401 [HN]) from AMED; by the National Cancer Center Research and Development Fund (no. 28-A-7 and no. 31-A-7 [HN]); by the Naito Foundation (YT and HN); by the Takeda Science Foundation (YT); by the Mitsubishi Foundation (YT); by the Tokyo Biochemical Research Foundation (YT); by the Daiichi Sankyo Foundation of Life Science (YT); by the Foundation for Promotion of Cancer Research in Japan (YT); by the Japanese Foundation for Multidisciplinary Treatment of Cancer Foundation (YT); by the Mochida Memorial Foundation for Medical and Pharmaceutical Research (YT); by the KANAE Foundation for the Promotion of Medical Science (YT); by the Yasuda Memorial Foundation for Medicine (YT); by the MSD Life Science Foundation (YT); by the Kowa Life Science Foundation (YT), by the Senri Life Science Foundation (YT); and by the Uehara Memorial Foundation (YT).
Funding Information:
Conflict of interest: YT received research grants and honoraria from Ono Pharmaceutical and Bristol-Myers Squibb; grants from KOTAI Biotechnology Inc. and Daiichi-Sankyo; and honoraria from AstraZeneca, Chugai Pharmaceutical, and MSD. HN received research grants and honoraria from Ono Pharmaceutical, Chugai Pharmaceutical, MSD, and Bristol- Myers Squibb and research grants from Taiho Pharmaceutical, Daiichi- Sankyo, Kyowa Kirin, Zenyaku Kogyo, Oncolys BioPharma, Debiopharma, Asahi-Kasei, Sysmex, Fujifilm, SRL, Astellas Pharmaceutical, Sumitomo Dainippon Pharma, and BD Japan.
Publisher Copyright:
© 2021, Inamori et al.
PY - 2021/5/10
Y1 - 2021/5/10
N2 - Patients with colorectal cancers (CRCs) generally exhibit improved survival through intensive lymph node (LN) dissection. However, recent progress in cancer immunotherapy revisits the potential importance of regional LNs, where T cells are primed to attack tumor cells. To elucidate the role of regional LN, we investigated the immunological status of nonmetastatic regional LN lymphocytes (LNLs) in comparison with those of the tumor microenvironment (tumor-infiltrating lymphocytes; TILs) using flow cytometry and next-generation sequencing. LNLs comprised an intermediate level of the effector T cell population between peripheral blood lymphocytes (PBLs) and TILs. Significant overlap of the T cell receptor (TCR) repertoire was observed in microsatellite instability-high/ mismatch repair-deficient (MSI-H/dMMR) CRCs with high tumor mutation burden (TMB), although limited TCRs were shared between nonmetastatic LNs and primary tumors in microsatellite stable/ MMR proficient (MSS/pMMR) CRC patients with low TMB. In line with the overlap of the TCR repertoire, an excessive LN dissection did not provide a positive impact on long-term prognosis in our MSI-H/dMMR CRC cohort (n = 130). We propose that regional LNs play an important role in antitumor immunity, particularly in MSI-H/dMMR CRCs with high TMB, requiring care to be taken regarding excessive nonmetastatic LN dissection in MSI-H/dMMR CRC patients.
AB - Patients with colorectal cancers (CRCs) generally exhibit improved survival through intensive lymph node (LN) dissection. However, recent progress in cancer immunotherapy revisits the potential importance of regional LNs, where T cells are primed to attack tumor cells. To elucidate the role of regional LN, we investigated the immunological status of nonmetastatic regional LN lymphocytes (LNLs) in comparison with those of the tumor microenvironment (tumor-infiltrating lymphocytes; TILs) using flow cytometry and next-generation sequencing. LNLs comprised an intermediate level of the effector T cell population between peripheral blood lymphocytes (PBLs) and TILs. Significant overlap of the T cell receptor (TCR) repertoire was observed in microsatellite instability-high/ mismatch repair-deficient (MSI-H/dMMR) CRCs with high tumor mutation burden (TMB), although limited TCRs were shared between nonmetastatic LNs and primary tumors in microsatellite stable/ MMR proficient (MSS/pMMR) CRC patients with low TMB. In line with the overlap of the TCR repertoire, an excessive LN dissection did not provide a positive impact on long-term prognosis in our MSI-H/dMMR CRC cohort (n = 130). We propose that regional LNs play an important role in antitumor immunity, particularly in MSI-H/dMMR CRCs with high TMB, requiring care to be taken regarding excessive nonmetastatic LN dissection in MSI-H/dMMR CRC patients.
UR - http://www.scopus.com/inward/record.url?scp=85105949876&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85105949876&partnerID=8YFLogxK
U2 - 10.1172/jci.insight.137365
DO - 10.1172/jci.insight.137365
M3 - Article
C2 - 33755600
AN - SCOPUS:85105949876
SN - 2379-3708
VL - 6
JO - JCI insight
JF - JCI insight
IS - 9
M1 - e137365
ER -